5 results match your criteria: "University of Miami School of Medicine and Sylvester Comprehensive Cancer Center[Affiliation]"
Letter to the Editor: The Need for Complete Population-Based Studies on the Etiology of Liver Disease.
Hepatology
June 2019
Department of Public Health Sciences, University of Miami School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.
BMC Cancer
August 2017
Hematology/Oncology, University of Miami School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Background: Describe a single-center real-world experience with comprehensive genomic profiling (CGP) to identify genotype directed therapy (GDT) options for patients with malignancies refractory to standard treatment options.
Methods: Patients who had CGP by a CLIA-certified laboratory between November 2012 and December 2015 were included. The medical records were analyzed retrospectively after Institutional Review Board (IRB) approval.
Psychometric validation and reliability analysis of a Spanish version of the patient satisfaction with cancer-related care measure: a patient navigation research program study.
Support Care Cancer
September 2012
University of Miami School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Background: Patient satisfaction (PS), a key measure of quality of cancer care, is a core study outcome of the multi-site National Cancer Institute-funded Patient Navigation Research Program. Despite large numbers of underserved monolingual Spanish speakers (MSS) residing in USA, there is no validated Spanish measure of PS that spans the whole spectrum of cancer-related care. The present study reports on the validation of the Patient Satisfaction with Cancer Care (PSCC) measure for Spanish (PSCC-Sp) speakers receiving diagnostic and therapeutic cancer-related care.
View Article and Find Full Text PDFTargeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.
Mol Cancer Ther
April 2011
Department of Medicine, University of Miami School of Medicine and Sylvester Comprehensive Cancer Center, 1475 N.W. 12th Avenue (D8-4) Miami, FL 33136, USA.
Article Synopsis
- Researchers created new anti-HER2 human endostatin fusion proteins to enhance the antitumor effects observed in previous studies with endostatin and anti-HER2 antibodies.
- The fusion protein huEndo-P125A was shown to be more effective at inhibiting tumor growth and improving survival rates in breast cancer models compared to other treatments, including individual components.
- The study suggests that using antibody fusion proteins to target endostatin can boost the effectiveness of cancer therapies, offering a potential new strategy for treating tumors with different targets.
Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.
Mol Cancer Ther
June 2005
Department of Medicine, Hematology-Oncology, University of Miami School of Medicine and Sylvester Comprehensive Cancer Center, FL 33136, USA.
Article Synopsis
- Endostatin inhibits angiogenesis and tumor growth, but its short serum half-life limits its effectiveness in human treatments, requiring frequent dosing.
- To address this, researchers created an antibody-endostatin fusion protein (anti-HER2 IgG3-endostatin) which has a significantly longer half-life and better targeting capabilities for HER2-positive tumors.
- The fusion protein showed greater efficacy in inhibiting tumor growth compared to regular endostatin and other treatments, suggesting that linking antiangiogenic proteins to targeting antibodies could improve cancer therapy.